MedTrace Logo

A Study Evaluating An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM and TGW

NCT05474313 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-09-21

No results posted yet for this study

Summary

The PrEP 3D randomized controlled trial (RCT) will study the effectiveness of the PrEP-3D app compared to standard of care for starting pre-exposure prophylaxis (PrEP), continuing PrEP, and adherence to PrEP.

Conditions

  • HIV Prevention
  • Pre-exposure Prophylaxis (PrEP)
  • Risk Reduction
  • Adherence, Medication

Interventions

BEHAVIORAL

PrEP-3D package

A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.

BEHAVIORAL

Standard of Care

Participants are given local standard of care navigation for initiation of PrEP

Sponsors & Collaborators

  • San Francisco Department of Public Health

    collaborator OTHER_GOV

  • Alto Pharmacy

    collaborator UNKNOWN

  • Public Health Foundation Enterprises, Inc.

    lead OTHER

Principal Investigators

  • Susan Buchbinder, MD · Bridge HIV, San Francisco Department of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05474313 on ClinicalTrials.gov